DouglasKanterMarksMD

Oncology • New York, NY

Breast Cancer, Hematologic Oncology

Medical Oncologist

Join to view full profile

Dr. Marks is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Marks' full profile

Already have an account?

Office
177 Fort Washington Avenue
6mhbroom 635
New York, NY 10032
Phone+1 212-305-7115

Education & Training

New York Presbyterian Hospital (Columbia Campus)Fellowship, Hematology and Medical Oncology, 2015 - 2018
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 2012 - 2015
Icahn School of Medicine at Mount SinaiClass of 2012

Certifications & Licensure

NY State Medical License 2014 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

3 citations
Image-based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno-oncology Biomarker Working Group on Breast C...
Chowdhury Arif Jahangir, David B Page, Glenn Broeckx, Claudia A Gonzalez, Caoimbhe Burke
The Journal of Pathology. 2024-03-01
15 citations
Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno-Oncology Biomarker Working Group on...
David B Page, Glenn Broeckx, Chowdhury Arif Jahangir, Sara Verbandt, Rajarsi R Gupta
The Journal of Pathology. 2023-08-01
12 citations
Pitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer: A report of the International Immuno-Oncology Biomarker Working Group...
Jeppe Thagaard, Glenn Broeckx, David B Page, Chowdhury Arif Jahangir, Sara Verbandt
The Journal of Pathology. 2023-08-01

Lectures

Association of Akt inhibition with change in immunophenotype of tumor microenvironment (TME) in breast cancer (BC).
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

Merck-AstraZeneca Breast Cancer Drug Reduces Risk of Death by 28% in Patients Diagnosed Early, Clinical Trial ShowsDecember 21st, 2024
Chemotherapy for Breast Cancer Doesn’t Seem to Increase Risk of COVID-19 Infection or DeathJuly 7th, 2021
Breast Cancer Treatments Do Not Increase Risk of Covid-19 Infection or DeathMay 19th, 2021
Join now to see all